By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Chroma Therapeutics 

Abingdon      England
Phone: n/a Fax:



Start Up

Company News
Viracta Therapeutics Acquires Phase II Epigenetic Drug Candidate From Chroma Therapeutics 11/30/2016 7:57:01 AM
Chroma Therapeutics Release: Tosedostat Opal Study in Acute Myeloid Leukemia Published in Lancet Oncology 3/4/2013 11:51:59 AM
Chroma Therapeutics Extends Collaboration With GlaxoSmithKline (GSK) and Advances Novel Targeted Agent Towards Clinical Development; Receives Milestone Payment 1/3/2013 10:24:05 AM
Cell Therapeutics, Inc. (CTIC) and Chroma Therapeutics Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) 12/13/2011 7:58:02 AM
Chroma Therapeutics and Cell Therapeutics, Inc. (CTIC) Announce New Positive Interim Phase II Data for Tosedostat in AML OPAL Study, Revealed at American Society of Clinical Oncology 6/8/2011 9:33:05 AM
Chroma Therapeutics Release: New Tosedostat Data Selected for Oral Discussion Session at the 2011 American Society of Clinical Oncology Annual Meeting 5/25/2011 11:35:47 AM
Cell Therapeutics, Inc. (CTIC) Acquires Exclusive Marketing and Co-Development Rights in the Americas to Chroma Therapeutics' Tosedostat, a First in Class Tumor Selective Oral Therapy for Treatment of Blood Related and Other Cancers 3/14/2011 7:55:34 AM
Chroma Therapeutics to Present at 29th Annual J.P. Morgan Healthcare Conference 1/6/2011 10:39:08 AM
Chroma Therapeutics Advances Novel Targeted Agent into Development; Receives Milestone Payment from GlaxoSmithKline (GSK) 8/24/2010 11:32:42 AM
GlaxoSmithKline (GSK) Signs Potential $1 Billion Drug Deal with Chroma Therapeutics 6/23/2009 8:05:38 AM